Table 1.
4 days after initial BrdU injection | |||||
---|---|---|---|---|---|
Marker expression | Corresponding stages | Control (%) | Mutant (%) | P | |
BrdU+/Tbr2−/NeuroD− | Type 1/(mature neurons) | ↓ | 39.02 ± 0.32 | 22.3 ± 5.43 | 0.019 |
BrdU+/Tbr2+/NeuroD− | Type 2a | n.c. | 30.15 ± 2.66 | 34.61 ± 7.26 | 0.297 |
BrdU+/Tbr2+/NeuroD+ | Type 2b/3 | ↑ | 22.89 ± 2.33 | 42.33 ± 4.97 | 0.012 |
BrdU+/Tbr2−/NeuroD+ | Immature neurons | ↓ | 7.94 ± 1.2 | 0.76 ± 0.76 | 0.004 |
BrdU+/NeuN−/Calbindin− | Progenitor cells | n.c. | 34.55 ± 4.44 | 47.69 ± 8.7 | 0.125 |
BrdU+/NeuN+/Calbindin− | Immature neurons | n.c. | 50.79 ± 2.91 | 43.34 ± 7.19 | 0.196 |
BrdU+/NeuN+/Calbindin+ | Mature neurons | ↓ | 14.67 ± 1.53 | 8.97 ± 2.09 | 0.046 |
28 days after initial BrdU injection | |||||
---|---|---|---|---|---|
Marker expression | Corresponding stages | Control (%) | Mutant (%) | P | |
BrdU+/Tbr2−/NeuroD− | (Type 1)/mature neurons | ↓ | 94.44 ± 1.11 | 72.22 ± 6.19 | 0.012 |
BrdU+/Tbr2+/NeuroD− | Type 2a | ↓ | 4.44 ± 1.11 | 1.11 ± 1.11 | 0.050 |
BrdU+/Tbr2+/NeuroD+ | Type 2b/3 | ↑ | 0 ± 0 | 16.67 ± 6.67 | 0.033 |
BrdU+/Tbr2−/NeuroD+ | Immature neurons | ↑ | 1.11 ± 1.11 | 10 ± 0 | 0.001 |
BrdU+/NeuN−/Calbindin− | Progenitor cells | n.c | 30 ± 5.77 | 40 ± 1.92 | 0.088 |
BrdU+/NeuN+/Calbindin− | Immature neurons | ↑ | 26.67 ± 6.67 | 54.44 ± 1.11 | 0.007 |
BrdU+/NeuN+/Calbindin+ | Mature neurons | ↓ | 43.33 ± 3.33 | 5.56 ± 1.11 | 0.0002 |
Data are expressed in % of total number of BrdU‐positive cells counted; arrows indicate increase or decrease of parameters determined. P, P‐value; error bars, SEM; significance, P ≤ 0.05; n = 3. n.c., not changed.